C&EN White Paper
Achieving Safety, Efficiency, and Flexibility in ADC Manufacturing
Brought to you by Repligen
Overview

Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the potency of highly cytotoxic payloads to deliver targeted cancer therapies. Manufacturing ADCs remains demanding: extremely potent payloads require stringent containment, organic solvents can promote aggregation, and achieving an optimal drug-to-antibody ratio (DAR) places pressure on manufacturers.

The white paper reviews these hurdles and explains how closed, single-use systems can support reliable and scalable ADC production. It also provides results for an extractables study of single-use tubing and filter components used in settings relevant to ADC manufacturing.

Key Objectives:
  • The importance of ADCs in cancer therapy and the distinct manufacturing challenges they present.
  • How the use of closed, single-use systems in ADC manufacturing enhances safety, efficiency, and flexibility.
  • Demonstrate through a case study how single-use assemblies show negligible extractables in simulated real-world conditions.

Brought to you by:
Repligen logo
Please complete the form to download the white paper.
*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society and its sponsor via email. You understand that you can withdraw your consent at any time. ACS takes your privacy seriously. For more information, please see the ACS Privacy Policy.

Copyright © 2025 American Chemical Society | 1155 Sixteenth Street NW | Washington, DC 20036 | View our Privacy Policy